Skip to main content

Table 4 Multivariate analysis assessing haemoglobin changes per treatment arm during different post-treatment follow-up visits

From: Delayed anemia assessment in patients treated with oral artemisinin derivatives for uncomplicated malaria: a pooled analysis of clinical trials data from Mali

 

Day 7 (n=2,657)

Day 14 (n=4,638)

Day 28 (n=4,082)

Covariates**

β* (95% CI)

p

β* (95% CI)

p

β* (95% CI)

p

AL

−0.21 (−0.48-0.05)

0.11

−0.06 (−0.17- 0.06)

0.34

−0.05 (−0.18- 0.08)

0.47

AS+partners

−0.34 (−0.57- -0.11)

0.003

−0.12 (−0.22- -0.02)

0.02

−0.03 (−0.14- 0.08)

0.62

AS

−0.69 (−0.95- -0.44)

<0.001

−0.03 (−0.18-0.11)

0.68

0.15 (−0.02-0.32)

0.08

<5 years old

−0.61 (−0.71- -0.51)

<0.001

−0.62 (−0.71- -0.54)

<0.001

−0.51 (−0.60- -0.42)

<0.001

Haemo day 0

0.56 (0.53-0.59)

<0.001

0.48 (0.46-0.50)

<0.001

0.45 (0.43-0.47)

<0.001

P. f. day 0

−0.43 (−0.51- -0.35)

<0.001

−0.33 (−0.40- -0.026)

<0.001

−0.04 (−0.12-0.04)

0.29

Treat fail

−0.40 (−0.59- -0.20)

0.018

−0.25 (−0.39- -0.11)

<0.001

−0.4 (−0.51- -0.29)

<0.001

  1. Note: *β is the regression coefficient estimate obtained from the generalized linear latent and mixed models using site as random effect;
  2. **Covariates references were: CQ, AQ, SP for day 7 and CQ, AQ, SP and SP-AQ for day 14 and day 28 for treatment, the age ≥5 years old for the age group, the 28-day cured parasite outcome after treatment for the treatment failure (Treat fail) outcome, the baseline parasite density was log transformed and treated as continuous variable; AS + partners were: AS-AQ, AS-SP, AS-PYR for day 7, AS-AQ, AS-SP, AS-MEF for day 14 and AS-AQ, AS-SP, AS-PYR, AS-SMP and AS-MEF for day 28.
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us